Litcius/Paper detail

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

Feng Wang, Ying Jin, Min Wang, Hui Luo, Weijia Fang, Yingnan Wang, Yan‐Xing Chen, Run-Jie Huang, Wen‐Long Guan, Jibin Li, Yuhong Li, Feng‐Hua Wang, Xiaohua Hu, Yanqiao Zhang, Miao‐Zhen Qiu, Lulu Liu, Zixian Wang, Chao Ren, De‐Shen Wang, Dong‐Sheng Zhang, Zhi‐Qiang Wang, Wenting Liao, Lin Tian, Qi Zhao, Rui‐Hua Xu

2024Nature Medicine165 citationsDOI

Topics & Concepts

BevacizumabClinical endpointMedicineInternal medicinePhases of clinical researchPopulationColorectal cancerOncologySurvival rateAngiogenesis inhibitorCancer researchGastroenterologyCancerChemotherapyClinical trialEnvironmental healthColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial | Litcius